
Questcor adds Elan president to its Board
pharmafile | November 15, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Elan, Questcor, martin
Biopharma firm Questcor Pharmaceuticals has appointed Elan’s president and chief executive G. Kelly Martin to its Board of directors.
Martin has served at Elan since early 2003 and during his tenure there led a strategic plan to restructure its business and built a diverse portfolio of scientific, clinical and therapeutic assets Questcor says.
“Questcor management and members of the board have known Kelly Martin for several years, having interacted with him and Elan twice regarding possible collaborations,” said Virgil Thompson, chairman of Questcor’s Board of directors.
Martin added: “I have had the opportunity to get to know Questcor and interact with management on several occasions over the past few years and admire its passion, tenacity and integrity.”
Prior to joining Elan Martin spent over 20 years at Merrill Lynch, managing a broad array of operating and executive responsibilities on a global basis, and served as head of the International Private Client Group.
Related Content

Perrigo acquires Omega for $4.5 billion
In a deal worth $4.5 billion Perrigo has announced the acquisition of over-the-counter (OTC) drugmaker …

Edelman buys Elan to ‘challenge’ the French PR industry
Edelman has swooped in on fellow PR firm Elan to create a ‘new player’ in …

Perrigo pays $8.6 billion for Elan
Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a …






